Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390509 | 0.94 | CA1 (0.46) | CA1CA2CA7USP2CA4 | |
| SCHEMBL9816232 | 0.91 | CA1 (0.52) | CA1CA2CA7USP2CA4 | |
| SCHEMBL30390130 | 0.88 | CA1 (0.49) | CA1CA2CA7USP2CA4 | |
| SCHEMBL3229826 | 0.85 | CA1 (0.48) | CA1CA2CA7USP2CA4 | |
| SCHEMBL87983 | 0.84 | CA1 (0.45) | CA1CA2CA7CA9 | |
| SCHEMBL4931536 | 0.84 | CA1 (0.45) | CA1CA2CA7CA9 | |
| SCHEMBL12937808 | 0.84 | CA1 (0.52) | CA1CA2CA7USP2CA4 | |
| SCHEMBL12937811 | 0.84 | CA1 (0.52) | CA1CA2CA7USP2CA4 | |
| SCHEMBL15025253 | 0.84 | CA1 (0.52) | CA1CA2CA7USP2CA4 | |
| SCHEMBL12937806 | 0.82 | CA1 (0.50) | CA1CA2CA7USP2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2939999-B1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | DOW CORNING TORAY CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9663432-B2 | High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same | DOW CORNING TORAY CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160052849-A1 | High-Purity Monoalkenyl-Containing Glycerin Derivative, And Method For Producing Same | Dow Coming Toray Co., Ltd. (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2939999-A1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | Dow Corning Toray Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052849-A1 | High-Purity Monoalkenyl-Containing Glycerin Derivative, And Method For Producing Same | GK, GYPA, NOTUM | CA1 4556/4885CA2 4423/4885CA7 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.